Lin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lin Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chuchu Xi
Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development China Pharmaceutical University Nanjing China
1 shared publication - Fang Zhao
Department of TCM Pharmacology, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China
1 shared publication - Heng Zhang
Institute of Molecular Physiology Shenzhen Bay Laboratory Shenzhen China
1 shared publication - Hongrong Fu
Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development China Pharmaceutical University Nanjing China
1 shared publication - Michael Xi Zhu
Institute of Molecular Physiology Shenzhen Bay Laboratory Shenzhen China
1 shared publication - Xiao Zhang
Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development China Pharmaceutical University Nanjing China
1 shared publication
Latest Publications
- 9 October 2026
- Published by Wiley in British Journal of Pharmacology
TRPV3 drives lung injury by sensing inflammatory signals to disrupt alveolar epithelial barrier and promote inflammation
Background and Purpose: Pulmonary inflammation is a central pathological feature of many respiratory diseases. Transient receptor potential vanilloid 3 (TRPV3), a non‐selective cation channel abundantly expressed in the skin, nerve and lung tissues, is involved in itch, skin inflammation and barrier regulation. However, its function in the pulmonary system remains elusive. We aimed to determine whether and how TRPV3 is involved in pulmonary inflammation. Experimental Approach: Lipopolysaccharide (LPS) and carvacrol were used to model acute lung injury (ALI) in C57BL/6J mice. Histology, bronchoalveolar lavage fluid analysis, qPCR, Western blotting, immunofluorescence, Ca 2+ imaging, transepithelial electrical resistance and FITC‐dextran permeability assays were used to assess inflammatory cell infiltration, cytokine expression, intracellular Ca 2+ changes and epithelial barrier integrity. Key Results: TRPV3 expression is markedly up‐regulated in lung tissues of ALI mice. Pharmacological activation of TRPV3 by carvacrol triggers features of ALI. Genetic deletion or pharmacological inhibition of TRPV3 significantly attenuated LPS‐ or carvacrol‐induced lung injury. Activating TRPV3 in cultured alveolar epithelial cells increased intracellular Ca 2+ , boosted cytokine/chemokine production, disrupted tight junctions, reduced transepithelial electrical resistance and increased epithelial permeability. TNF‐α augmented TRPV3 Ca 2+ responses, and inhibition of TRPV3 activity or suppression of TRPV3 expression abolished TNF‐α‐induced production of cytokines/chemokines and tight junction disruption. Conclusions and Implications: TRPV3 senses inflammatory signals to augment inflammation and disrupt tight junctions in alveolar epithelial cells, making it a promising molecular target to develop treatments for pulmonary inflammation.
- 9 October 2026
- Published by Wiley in British Journal of Pharmacology
TRPV3 drives lung injury by sensing inflammatory signals to disrupt alveolar epithelial barrier and promote inflammation
Background and Purpose: Pulmonary inflammation is a central pathological feature of many respiratory diseases. Transient receptor potential vanilloid 3 (TRPV3), a non‐selective cation channel abundantly expressed in the skin, nerve and lung tissues, is involved in itch, skin inflammation and barrier regulation. However, its function in the pulmonary system remains elusive. We aimed to determine whether and how TRPV3 is involved in pulmonary inflammation. Experimental Approach: Lipopolysaccharide (LPS) and carvacrol were used to model acute lung injury (ALI) in C57BL/6J mice. Histology, bronchoalveolar lavage fluid analysis, qPCR, Western blotting, immunofluorescence, Ca 2+ imaging, transepithelial electrical resistance and FITC‐dextran permeability assays were used to assess inflammatory cell infiltration, cytokine expression, intracellular Ca 2+ changes and epithelial barrier integrity. Key Results: TRPV3 expression is markedly up‐regulated in lung tissues of ALI mice. Pharmacological activation of TRPV3 by carvacrol triggers features of ALI. Genetic deletion or pharmacological inhibition of TRPV3 significantly attenuated LPS‐ or carvacrol‐induced lung injury. Activating TRPV3 in cultured alveolar epithelial cells increased intracellular Ca 2+ , boosted cytokine/chemokine production, disrupted tight junctions, reduced transepithelial electrical resistance and increased epithelial permeability. TNF‐α augmented TRPV3 Ca 2+ responses, and inhibition of TRPV3 activity or suppression of TRPV3 expression abolished TNF‐α‐induced production of cytokines/chemokines and tight junction disruption. Conclusions and Implications: TRPV3 senses inflammatory signals to augment inflammation and disrupt tight junctions in alveolar epithelial cells, making it a promising molecular target to develop treatments for pulmonary inflammation.